WILMINGTON, DE, October 1, 2024 – Enovis™ (NYSE: ENOV), an innovation-driven medical technology company, has announced its strategic partnership with Ossium Health®, a clinical-stage biotechnology company, to distribute OssiGraft™ and OssiGraft Prime™—cryopreserved viable bone matrix (VBX) allografts—through Enovis’ extensive sales network.
The allografts consist of 100% viable bone in a demineralization-free solution, with 80% cancellous bone. This composition optimizes bone healing as research suggests the cancellous bone enables faster revascularization in just two weeks, compared to the two-month process required for cortical bone.1,2 With an average donor age of 35, OssiGraft and OssiGraft Prime deliver remarkable biological vitality, allowing them to compete with competitors in efficacy3,4.
These biological advantages are critical, as the success of intricate fusion procedures relies on the synergy between mechanical stability and biological support. To meet this mechanical stability demand, the Enovis product portfolio provides a comprehensive selection of carefully engineered solutions, such as the DynaNail™ TTC Fusion System, which utilizes sustained dynamic compression technology. When structural reinforcement and biological foundation combine, patients experience a seamless recovery process due to successful fusion.
“Our newly forged alliance with Ossium Health enriches our portfolio with invaluable allograft solutions,” said Gary Justak, President and General Manager of Enovis Foot & Ankle. “By integrating these premium grafts into our distribution network, we are expanding our capacity to provide surgeons with advanced products that redefine surgical results and elevate patient care.”
About Enovis
Enovis™ (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.
About Ossium Health
Ossium Health® is a biotechnology company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with blood, immune, and orthopedic diseases. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & EVP. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendment (CLIA).
Media Contact
Diana Aldermae
Enovis Foot & Ankle
Diana.Aldermae@enovis.com
References
- Kumagai, K. et al. 2008. J. Ortho. Res. / Liu, R. et al. 2011. BMC Muscuskelet. Disord. / Neagu, T. et al. 2016. Rom. J. Morphol. Embryol. Rabie, A. B., et al. 1996. Int. J. Oral Maxillofac. Surg. /Colnot, C. 2009. J. Bone Miner. Res. / Suh, K.T. et al. 2012. J. Magn. Reson. Imaging / Siclari, V.A. et al. 2013. Bone 53, 575-586.
- Bell, G et al. 2005. Spine Surgery (Bone Graft harvesting).
- Becker's Spine Review. (2023, September 20). OssiGraft Prime used in first orthopedic case.
- Chen, T. et al. 2018. Sci. Res.